Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 18/20 | 1.00 |
| ▸ | BACE1 | P56817 | 1/20 | 0.58 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.49 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2089350 | 0.87 | CA2 (1.00) | CA2 | |
| SCHEMBL2176133 | 0.84 | CA2 (0.72) | CA2BACE1PDE3BPDE3A | |
| SCHEMBL10372421 | 0.83 | CA2 (0.70) | CA2 | |
| SCHEMBL10368744 | 0.82 | CA2 (0.80) | CA2 | |
| SCHEMBL10369174 | 0.79 | CA2 (1.00) | CA2 | |
| SCHEMBL2088019 | 0.78 | CA2 (0.65) | CA2 | |
| SCHEMBL10369130 | 0.78 | CA2 (0.63) | CA2 | |
| SCHEMBL3483161 | 0.78 | CA2 (0.63) | CA2 | |
| Hydrochloric Acid SCHEMBL10371505 | 0.78 | CA2 (0.63) | CA2 | |
| SCHEMBL10371815 | 0.78 | CA2 (0.63) | CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163778-B2 | Pyridines as FBPase inhibitors for treatment of diabetes | HOFFMANN-LA ROCHE INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20090143439-A1 | NEW PYRIDINES AS FBPASE INHIBITORS FOR TREATMENT OF DIABETES | HOFFMANN-LA ROCHE, INC. | 2009-06-04 | — | — | US | disclosed |
| EP-0129478-B1 | 2-SULFAMOYLBENZO (B) THIOPHENE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ELEVATED INTRAOCULAR PRESSURE | MERCK & CO. INC. (US) | 1990-01-17 | — | — | EP | disclosed |
| US-4788192-A | TOPICALLY APPLYING; FOR GLAUCOMA | MERCK & CO., INC. (US) | 1988-11-29 | — | — | US | disclosed |
| US-4668697-A | Elevated intraocular pressure lowering benzo-[b]-thiophene-2-sulfonamide derivatives, compositions, and method of use therefor | MERCK & CO., INC. (US) | 1987-05-26 | — | — | US | disclosed |
| EP-0129478-A2 | 2-Sulfamoylbenzo (b) thiophene derivatives, their preparation and pharmaceutical composition for the treatment of elevated intraocular pressure | MERCK & CO. INC. (US) | 1984-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143439-A1 | NEW PYRIDINES AS FBPASE INHIBITORS FOR TREATMENT OF DIABETES | FBP1, PDXK, G6PC1 | CA2 1000/4885BACE1 1273/4885PDE3B 845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.